Dateline Introduction
November 17, 2025 — Marlborough, Massachusetts — Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company advancing RNA-based immuno-oncology therapeutics, announced its upcoming podium presentation at the Advanced Therapies USA 2025 Congress, taking place December 10–12 in Philadelphia. The company will highlight new scientific and translational progress from its INTASYL® self-delivering siRNA technology, reinforcing growing momentum behind its programs aimed at enhancing antitumor immunity in difficult-to-treat cancers. This visibility reflects Phio’s strengthening position in the next wave of targeted RNA therapeutics.
Science Significance
Phio’s presentation will focus on the advancements of INTASYL®, a self-delivering siRNA platform designed to silence specific immune-regulatory targets directly inside tumor microenvironments without requiring formulation technologies or delivery vehicles. The scientific relevance is substantial: INTASYL’s ability to penetrate cells and modulate gene expression enables a precision-driven immune activation approach, supporting enhanced T-cell and NK-cell killing of cancer cells. Such mechanisms represent a major leap forward from earlier RNA therapeutic models, achieving targeted gene silencing with improved stability, tumor penetration and local activity. Presenting this data at ATUSA underscores the emerging role of self-delivering RNA technologies as a powerful category in immuno-oncology research.
Regulatory Significance
While the podium presentation itself does not constitute a regulatory submission, it plays an important role in shaping future GxP-aligned development. Data shared at ATUSA will inform the company’s ongoing interactions with regulators regarding IND-enabling studies, trial design and future clinical-development pathways for lead candidates, including PH-762, targeting PD-1 in cutaneous carcinomas. As RNA therapeutics face heightened scrutiny around manufacturing consistency, bio-distribution and safety, public disclosure of scientific findings strengthens Phio’s regulatory transparency and positions the company to engage more effectively in pre-IND, IND and early-phase clinical discussions. Such scientific communication aligns with FDA expectations for robust mechanism-of-action understanding and clear translational rationale.
Business Significance
Advertisement
From a business perspective, the upcoming presentation enhances Phio’s visibility among partners, investors and strategic collaborators across the advanced-therapies ecosystem. Conference podium sessions—particularly at high-profile events—help strengthen confidence in Phio’s pipeline value, scientific leadership and competitive advantage within RNA therapeutics. By showcasing validated data supporting tumor-targeted gene silencing, the company reinforces the potential of INTASYL to expand into multiple oncology indications, opening doors for licensing, co-development agreements and future capital investment. In a market increasingly shaped by next-generation immunotherapies, the event elevates Phio’s profile and supports the company’s business strategy anchored in high-impact, differentiated science.
Patients’ Significance
For patients, particularly those battling cutaneous squamous cell carcinoma and other solid tumors, the continued advancement of INTASYL-based therapeutics offers promising new avenues for treatment. Traditional immunotherapies do not work for all patients, and INTASYL’s targeted approach may overcome limitations linked to tumor immune suppression. By enhancing T-cell activity directly within the tumor, Phio’s programs could deliver more potent, tumor-localized immune responses with fewer systemic effects. Sharing upcoming data contributes to accelerating clinical readiness, moving these therapies closer to trials where patients could benefit from more precise, flexible and durable anti-tumor immune activation.
Policy Significance
The podium presentation also reflects the increasing alignment between scientific innovation and health-policy priorities surrounding advanced therapeutics, RNA platforms and targeted immuno-oncology. Regulatory bodies and health-policy groups continue emphasizing the need for transparent, evidence-based development of emerging modalities like siRNA. By publicly presenting mechanistic and preclinical results, Phio supports policy goals around responsible innovation, ethical clinical translation and equitable access to next-generation oncology treatments. The company’s approach reinforces a broader shift toward precision medicine frameworks, where gene-modulating therapies are designed to deliver highly specific effects while supporting long-term system-wide safety standards.
Phio Pharmaceuticals’ participation in Advanced Therapies USA 2025 underscores its leadership in self-delivering RNA therapeutics and advances its strategic mission to develop transformative immuno-oncology treatments. With the INTASYL platform gaining visibility and maturing toward future clinical milestones, the upcoming presentation marks an important step in connecting pioneering science with real-world therapeutic potential. As the field of advanced therapies accelerates, Phio’s continued progress positions it as a key innovator shaping the future landscape of oncology treatment.
Source: Phio Pharmaceuticals Corp. press release
